Impact on social media platforms from reduced compulsive use vs. AI-driven growth.
Projected 20-Year Change
-4.5%
-$35.7B annually
Food has been a source of conflict and a tool of power throughout human history. A structural decline in global food demand, driven by HOTs, would alter the geopolitical landscape in several interconnected ways.
Agricultural trade dependencies
The current global food trade network creates dependencies that shape diplomatic relationships and exert geopolitical leverage. Countries like Russia, Ukraine, Argentina, Australia, Brazil, India, Canada, Thailand, France, and New Zealand derive significant economic and geopolitical weight from being major exporters of grains, sugar, dairy, and other agricultural products. If global demand for these products declines substantially these exporting nations will face economic pressure. Nations that import these foods will benefit from reduced import costs but trade balances, and therefore diplomatic leverage, will shift.
Pharmaceutical supply chain security
The most strategically consequential dimension may be manufacturing dependency. The drugs that will improve the health of hundreds of millions of people are, at present, produced primarily by a small number of large pharmaceutical companies concentrated in the US and Europe. Nations that are dependent on foreign supply for a technology this consequential, that affects workforce health, military readiness, and long-term demographic vitality, face a structural vulnerability. The staggered patent expiration timeline (semaglutide expiring in 2026 in China, India, and Canada but not the US and EU until 2031) already creates differential access that maps onto existing geopolitical fault lines. Nations that develop domestic HOT manufacturing capacity gain resilience while those that don't face dependence.
Differential adoption creating new inequalities
Nations that mobilize HOTs adoption earliest will have healthier, more productive, longer-lived populations within a decade or two. This is a competitive advantage that compounds over time. Early movers in this health transition may pull ahead of slower adopters in ways that are difficult to reverse. A new axis of geopolitical inequality could emerge between HOTs-accessible and HOTs-denied populations, layered onto existing disparities in wealth, education, and political stability.
Drug cartel destabilization
GLP-1 drugs demonstrably reduce cravings for opioids, cocaine, alcohol, and other addictive substances. Widespread HOT adoption could meaningfully erode demand for illicit drugs, threatening the revenue base of cartels and narco-states whose political economies are partially organized around drug production, trafficking, and the corruption they fund. Mexico, Colombia, Afghanistan, and other nations where cartels and drug production play a significant role in political and economic life would face structural pressure. Whether this is destabilizing or stabilizing depends on the speed of the transition and whether governance institutions are capable of managing the adjustment.
We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.
The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.
Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.
Learn more about the HOT disruption and its implications for health, society, and the economy.
Disclaimer
The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.